Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-07-31

Precigen (PGEN)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$5,354,329
Helen Sabzevari total, FY2025
75th
CEO pay percentile vs peers
34:1
CEO-to-median pay ratio
98.68%
Say-on-pay support, latest vote
Companies that benchmark against PGEN
3 companies name PGEN as a compensation peer

Each company listed discloses PGEN in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named PGEN in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Helen Sabzevari$1,000,000$0$2,215,000$1,069,200$1,049,997$0$20,132$5,354,329
President and Chief Executive Officer
Rutul Shah485,0000499,899384,912145,498045,6031,560,912
Chief Operating Officer
Harry Thomasian Jr.488,0000464,970374,220131,758035,7571,494,705
Chief Financial Officer
Donald Lehr575,0000408,751267,300132,249046,8961,430,196
Chief Legal Officer
Phil Tennant510,0000271,103267,300137,700043,8531,229,956
Chief Commercial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Helen Sabzevari$5,354,329$5,431,895$3,719,061−77,566
Rutul Shah1,560,9121,407,5441,037,974+153,368
Harry Thomasian Jr.1,494,7051,402,4521,131,910+92,253
Donald Lehr1,430,1961,352,0801,064,695+78,116
Phil Tennant1,229,956518,337+711,619

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Harry Thomasian Jr.Chief Financial Officer2026-05-23D87,500$0$0Derivative, Class A CommonForm 4 ↗
Helen SabzevariPresident and CEO2026-05-23A250,000CommonForm 4 ↗
Phil TennantChief Commercial Officer2026-05-23A62,500CommonForm 4 ↗
Phil TennantChief Commercial Officer2026-05-23D62,50000Derivative, Class A CommonForm 4 ↗
Rutul ShahChief Operating Officer2026-05-23D90,00000Derivative, Class A CommonForm 4 ↗
Donald LehrChief Legal Officer2026-05-23D62,50000Derivative, Class A CommonForm 4 ↗
Harry Thomasian Jr.Chief Financial Officer2026-05-23A87,500CommonForm 4 ↗
Rutul ShahChief Operating Officer2026-05-23A90,000CommonForm 4 ↗
Helen SabzevariPresident and CEO2026-05-23D250,00000Derivative, Class A CommonForm 4 ↗
Donald LehrChief Legal Officer2026-05-23A62,500CommonForm 4 ↗
Harry Thomasian Jr.Chief Financial Officer2026-05-28D41,8844182,614CommonForm 4 ↗
Helen SabzevariPresident and CEO2026-05-28D119,2504519,930CommonForm 4 ↗
Phil TennantChief Commercial Officer2026-05-28D30,2724131,986CommonForm 4 ↗
Rutul ShahChief Operating Officer2026-05-28D42,7034186,185CommonForm 4 ↗
Donald LehrChief Legal Officer2026-05-28D29,1314127,011CommonForm 4 ↗
Helen SabzevariPresident and CEO2026-06-29D346,83600Derivative, Class A CommonForm 4 ↗
Harry Thomasian Jr.Chief Financial Officer2026-06-29D28,5716165,140CommonForm 4 ↗
Harry Thomasian Jr.Chief Financial Officer2026-06-29D171,4296948,002CommonForm 4 ↗
Rutul ShahChief Operating Officer2026-06-29D42,92400Derivative, Class A CommonForm 4 ↗
Rutul ShahChief Operating Officer2026-06-29A42,9242100,013CommonForm 4 ↗
Rutul ShahChief Operating Officer2026-06-29D42,9246251,105CommonForm 4 ↗
Helen SabzevariPresident and CEO2026-06-29A346,8362808,128CommonForm 4 ↗
Helen SabzevariPresident and CEO2026-06-29D346,83662,042,864CommonForm 4 ↗
Harry Thomasian Jr.Chief Financial Officer2026-07-31D100,0006606,000CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Helen SabzevariRSU2025-06-26500,000$715,000
Donald LehrOPTION2025-05-23250,000267,300
Helen SabzevariOPTION2025-05-231,000,0001,069,200
Phil TennantRSU2025-06-26125,000178,750
Helen SabzevariRSU2025-04-171,079,1371,500,000
Donald LehrRSU2025-06-26125,000178,750
Donald LehrRSU2025-04-17165,468230,001
Rutul ShahRSU2025-06-26180,000257,400
Harry Thomasian Jr.RSU2025-06-26175,000250,250
Phil TennantOPTION2025-05-23250,000267,300
Rutul ShahOPTION2025-05-23360,000384,912
Rutul ShahRSU2025-04-17174,460242,499
Harry Thomasian Jr.RSU2025-04-17154,475214,720
Harry Thomasian Jr.OPTION2025-05-23350,000374,220
Phil TennantRSU2025-04-1766,44192,353
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Helen Sabzevari$2,215,000$0$1,069,2000.0%
Donald Lehr408,7510267,3000.0%
Phil Tennant271,1030267,3000.0%
Rutul Shah499,8990384,9120.0%
Harry Thomasian Jr.464,9700374,2200.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Harry Thomasian Jr.RSU175,000$731,500
Rutul ShahOption332,2921.4
Phil TennantRSU125,000522,500
Harry Thomasian Jr.Option50,0002.33
Rutul ShahRSU180,000752,400
Helen SabzevariRSU500,0002,090,000
Donald LehrRSU125,000522,500
Helen SabzevariOption1,089,3131.4
Rutul ShahOption360,0001.37
Harry Thomasian Jr.Option173,6671.21
Donald LehrOption241,6671.4
Donald LehrOption250,0001.37
Phil TennantOption250,0001.37
Phil TennantOption129,1671.61
Donald LehrOption37,5002.33
Harry Thomasian Jr.Option302,0841.4
Rutul ShahOption50,0002.33
Helen SabzevariOption1,000,0001.37
Donald LehrOption100,0001.21
Helen SabzevariOption577,4341.21
Harry Thomasian Jr.Option350,0001.37
Rutul ShahOption166,6671.21
Helen SabzevariOption211,7502.33
05

Incentive-plan design — the Compensation Discussion & Analysis

Our compensation philosophy is guided by the principle of pay-for-performance. Our compensation programs are designed to support our business goals by rewarding achievement of short-term and progress towards long-term objectives in a manner that links compensation of our executive officers with the value created for our shareholders.

CEO STI target (% of salary)150%
CEO LTI target (% of salary)
Independent consultantAon
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-24208,241,7392,790,8791,254,23298.68%Passed
20252025-06-30175,928,0613,683,746419,97897.95%Passed
20242024-07-05144,115,0683,413,0361,299,10897.69%Passed
20232023-06-08142,885,7495,521,791503,46996.28%Passed
20222022-06-0995,256,02526,635,6291,441,94278.15%Passed
20212021-06-10101,077,69023,552,337371,72281.1%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-2498.68%a
20252025-06-3097.95%b
20242024-07-0597.69%c

a. Approved under the standard stated in the filing — “A "majority" of votes cast means that more votes were cast "for" the proposal than "against." Abstentions and broker non-votes (described under "How are abstentions and broker non-votes counted?") are not considered as votes cast and will have no effect on the vote outcome for Proposals 1, 2, 3, and 4, except that as Proposal 2 is considered "routine," the Board anticipates that there will be no broker non-votes with respect to such proposal.”.

b. Approved under the standard stated in the filing — “A "majority" of votes cast means that more votes were cast "for" the proposal than "against." Abstentions and broker non-votes (described under "How are abstentions and broker non-votes counted?") are not considered as votes cast and will have no effect on the vote outcome for Proposals 1, 2, 3, 4, 5, 6 and 7, except that as Proposals 2 and 4 are considered "routine," there will be no 2 TABLE OF CONTENTS broker non-votes with respect to such proposals.”.

c. Approved under the standard stated in the filing — “A "majority" of votes cast means that more votes were cast "for" the proposal than "against." Abstentions and broker non-votes (described under "How are abstentions and broker non-votes counted?") are not considered as votes cast and will have no effect on the vote outcome for Proposals 1, 2,3 and 4.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)34 : 1
CEO total compensation$5,354,329
Median employee compensation$159,500
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Randal KirkIndependent · Board Chair$100,000$250,000$250,000$0$600,000
Jeffrey KindlerIndependent · Audit (Chair) · Compensation69,000125,000125,0000319,000
Fred HassanIndependent · Compensation · Audit63,000125,000125,0000313,000
Vinita GuptaIndependent · Nominating/Governance · Audit63,000125,000125,0000313,000
Cesar AlvarezIndependent · Nominating/Governance (Chair)62,500125,000125,0000312,500
James TurleyIndependent · Lead Independent Director · Compensation (Chair)62,500125,000125,0000312,500
Nancy Howell AgeeIndependent · Nominating/Governance56,500125,000125,0000306,500
Steven FrankIndependent50,000125,000125,0000300,000
Helen SabzevariEmployee director00000
09

Board fee structure and ownership guideline

Annual cash retainer$50,000
Annual equity retainer$250,000
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)100,000
Stock ownership guideline5x annual cash retainer
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$526,500
Equity awards (grant-date value)$1,125,000
All other compensation$0
Total cost of the board$1,651,500

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Precigen names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Precigen.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Day One Biopharmaceuticals2024Jeremy Bender$680,000$2,700,280$2,664,697$501,800$6,560,577
2Replimune Group2026Sushil Patel700,0003,376,0031,448,325315,0005,845,982
3Precigen2025Helen Sabzevari1,000,0002,215,0001,069,2001,049,9975,354,329
4Aura Bioscience2025Elisabet de los Pinos645,4831,492,3781,513,293284,0133,956,167
5Rocket Pharmaceuticals2025Gaurav Shah671,076806,7511,613,377403,0483,510,241
Kyverna Therapeuticsnot in coverage universe

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Precigen140%not disclosednot disclosedAon
Aura Biosciencenot disclosednot disclosednot disclosedPay Governance
Day One Biopharmaceuticals123%Options 50 · RSU 50not disclosedCompensia Inc.
Kyverna Therapeuticsnot disclosednot disclosednot disclosednot disclosed
Replimune Groupnot disclosednot disclosedNoPearl Meyer
Rocket Pharmaceuticalsnot disclosednot disclosednot disclosedSemler Brossy

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Helen SabzevariDEF 14A2026-04-300001140361-26-018214Section “Summary Compensation Table” · page 43. As printed: 5,354,329. Filing ↗machine: r2 · c24 · span 721439–721448
2Section 01, Rutul ShahDEF 14A2026-04-300001140361-26-018214Section “Summary Compensation Table” · page 43. As printed: 1,560,912. Filing ↗machine: r11 · c24 · span 761596–761605
3Section 01, Harry Thomasian Jr.DEF 14A2026-04-300001140361-26-018214Section “Summary Compensation Table” · page 43. As printed: 1,494,705. Filing ↗machine: t189 · r5 · c24 · span 734886–734895
4Section 01, Donald LehrDEF 14A2026-04-300001140361-26-018214Section “Summary Compensation Table” · page 43. As printed: 1,430,196. Filing ↗machine: r8 · c24 · span 747958–747967
5Section 01, Phil TennantDEF 14A2026-04-300001140361-26-018214Section “Summary Compensation Table” · page 43. As printed: 1,229,956. Filing ↗machine: r14 · c24 · span 774661–774670
6Section 03, Helen Sabzevari RSUDEF 14A2026-04-300001140361-26-018214Section “GRANTS OF PLAN-BASED AWARDS FOR 2025” · grants of plan-based awards table. Filing ↗machine: t163 · r2 · c6 · span 595396–595403
7Section 03, Donald Lehr OPTIONDEF 14A2026-04-300001140361-26-018214Section “GRANTS OF PLAN-BASED AWARDS FOR 2025” · grants of plan-based awards table. Filing ↗machine: t165 · r2 · c3 · span 627062–627069
8Section 03, Helen Sabzevari OPTIONDEF 14A2026-04-300001140361-26-018214Section “GRANTS OF PLAN-BASED AWARDS FOR 2025” · grants of plan-based awards table. Filing ↗machine: t157 · r2 · c3 · span 572577–572586
9Section 03, Phil Tennant RSUDEF 14A2026-04-300001140361-26-018214Section “GRANTS OF PLAN-BASED AWARDS FOR 2025” · grants of plan-based awards table. Filing ↗machine: t165 · r4 · c6 · span 630243–630250
10Section 03, Helen Sabzevari RSUDEF 14A2026-04-300001140361-26-018214Section “GRANTS OF PLAN-BASED AWARDS FOR 2025” · grants of plan-based awards table. Filing ↗machine: t163 · r2 · c6 · span 595394–595403
11Section 03, Donald Lehr RSUDEF 14A2026-04-300001140361-26-018214Section “GRANTS OF PLAN-BASED AWARDS FOR 2025” · grants of plan-based awards table. Filing ↗machine: t165 · r2 · c6 · span 627615–627622
12Section 03, Donald Lehr RSUDEF 14A2026-04-300001140361-26-018214Section “GRANTS OF PLAN-BASED AWARDS FOR 2025” · grants of plan-based awards table. Filing ↗machine: t196 · r12 · c22 · span 861982–861989
13Section 03, Rutul Shah RSUDEF 14A2026-04-300001140361-26-018214Section “GRANTS OF PLAN-BASED AWARDS FOR 2025” · grants of plan-based awards table. Filing ↗machine: t165 · r3 · c6 · span 628871–628878
14Section 03, Harry Thomasian Jr. RSUDEF 14A2026-04-300001140361-26-018214Section “GRANTS OF PLAN-BASED AWARDS FOR 2025” · grants of plan-based awards table. Filing ↗machine: t164 · r3 · c6 · span 621752–621759
15Section 03, Phil Tennant OPTIONDEF 14A2026-04-300001140361-26-018214Section “GRANTS OF PLAN-BASED AWARDS FOR 2025” · grants of plan-based awards table. Filing ↗machine: t165 · r4 · c3 · span 629714–629721
16Section 03, Rutul Shah OPTIONDEF 14A2026-04-300001140361-26-018214Section “GRANTS OF PLAN-BASED AWARDS FOR 2025” · grants of plan-based awards table. Filing ↗machine: t165 · r3 · c3 · span 628399–628406
17Section 03, Rutul Shah RSUDEF 14A2026-04-300001140361-26-018214Section “GRANTS OF PLAN-BASED AWARDS FOR 2025” · grants of plan-based awards table. Filing ↗machine: t196 · r16 · c22 · span 879195–879202
18Section 03, Harry Thomasian Jr. RSUDEF 14A2026-04-300001140361-26-018214Section “GRANTS OF PLAN-BASED AWARDS FOR 2025” · grants of plan-based awards table. Filing ↗machine: t196 · r8 · c22 · span 844714–844721
19Section 03, Harry Thomasian Jr. OPTIONDEF 14A2026-04-300001140361-26-018214Section “GRANTS OF PLAN-BASED AWARDS FOR 2025” · grants of plan-based awards table. Filing ↗machine: t164 · r3 · c3 · span 621297–621304
20Section 03, Phil Tennant RSUDEF 14A2026-04-300001140361-26-018214Section “GRANTS OF PLAN-BASED AWARDS FOR 2025” · grants of plan-based awards table. Filing ↗machine: t196 · r20 · c22 · span 896438–896444
21Section 07, pay ratioDEF 14A2026-04-300001140361-26-018214Section “CEO Pay Ratio”. As printed: 34 : 1. Filing ↗machine: t237 · span 1382971–1383058
22Section 08, Randal KirkDEF 14A2026-04-300001140361-26-018214Section “Director Compensation”. As printed: 600,000. Filing ↗machine: t126 · r2 · c12 · span 399497–399504
23Section 08, Jeffrey KindlerDEF 14A2026-04-300001140361-26-018214Section “Director Compensation”. As printed: 319,000. Filing ↗machine: t126 · r5 · c12 · span 406554–406561
24Section 08, Fred HassanDEF 14A2026-04-300001140361-26-018214Section “Director Compensation”. As printed: 313,000. Filing ↗machine: t126 · r7 · c12 · span 411372–411379
25Section 08, Vinita GuptaDEF 14A2026-04-300001140361-26-018214Section “Director Compensation”. As printed: 313,000. Filing ↗machine: t126 · r8 · c12 · span 413957–413964
26Section 08, Cesar AlvarezDEF 14A2026-04-300001140361-26-018214Section “Director Compensation”. As printed: 312,500. Filing ↗machine: t126 · r3 · c12 · span 401732–401739
27Section 08, James TurleyDEF 14A2026-04-300001140361-26-018214Section “Director Compensation”. As printed: 312,500. Filing ↗machine: t126 · r6 · c12 · span 409139–409146
28Section 08, Nancy Howell AgeeDEF 14A2026-04-300001140361-26-018214Section “Director Compensation”. As printed: 306,500. Filing ↗machine: t126 · r9 · c12 · span 416076–416083
29Section 08, Steven FrankDEF 14A2026-04-300001140361-26-018214Section “Director Compensation”. As printed: 300,000. Filing ↗machine: t126 · r4 · c12 · span 404317–404324
30Section 08, Helen SabzevariDEF 14A2026-04-300001140361-26-018214Section “Director Compensation”. As printed: 0. Filing ↗
31Section 02, Harry Thomasian Jr. 2026-05-23Form 42026-05-270000950103-26-007845Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Helen Sabzevari 2026-05-23Form 42026-05-270000950103-26-007842Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Phil Tennant 2026-05-23Form 42026-05-270000950103-26-007844Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Phil Tennant 2026-05-23Form 42026-05-270000950103-26-007844Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Rutul Shah 2026-05-23Form 42026-05-270000950103-26-007843Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Donald Lehr 2026-05-23Form 42026-05-270000950103-26-007841Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Harry Thomasian Jr. 2026-05-23Form 42026-05-270000950103-26-007845Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Rutul Shah 2026-05-23Form 42026-05-270000950103-26-007843Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Helen Sabzevari 2026-05-23Form 42026-05-270000950103-26-007842Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Donald Lehr 2026-05-23Form 42026-05-270000950103-26-007841Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Harry Thomasian Jr. 2026-05-28Form 42026-06-010000950103-26-008173Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Helen Sabzevari 2026-05-28Form 42026-06-010000950103-26-008168Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Phil Tennant 2026-05-28Form 42026-06-010000950103-26-008172Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Rutul Shah 2026-05-28Form 42026-06-010000950103-26-008170Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Donald Lehr 2026-05-28Form 42026-06-010000950103-26-008169Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Helen Sabzevari 2026-06-29Form 42026-07-010000950103-26-009978Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Harry Thomasian Jr. 2026-06-29Form 42026-07-010000950103-26-009980Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Harry Thomasian Jr. 2026-06-29Form 42026-07-010000950103-26-009980Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Rutul Shah 2026-06-29Form 42026-07-010000950103-26-009979Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Rutul Shah 2026-06-29Form 42026-07-010000950103-26-009979Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Rutul Shah 2026-06-29Form 42026-07-010000950103-26-009979Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Helen Sabzevari 2026-06-29Form 42026-07-010000950103-26-009978Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Helen Sabzevari 2026-06-29Form 42026-07-010000950103-26-009978Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Harry Thomasian Jr. 2026-07-31Form 42026-07-310000950103-26-011578Insider equity transaction reported since the proxy statement. Filing ↗
55Section 06, 2026 voteForm 8-K2026-06-240000950103-26-009441Item 5.07 · say-on-pay result. As reported: 98.68% (votes for as printed: 208,241,739). Filing ↗
56Section 06, 2025 voteForm 8-K2025-06-300000950103-25-008124Item 5.07 · say-on-pay result. As reported: 97.95% (votes for as printed: 175,928,061). Filing ↗
57Section 06, 2024 voteForm 8-K2024-07-050000950103-24-009693Item 5.07 · say-on-pay result. As reported: 97.69% (votes for as printed: 144,115,068). Filing ↗
58Section 01 trend, Δ column (computed)ComputedcomputedΔ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
59Section 03b vehicle mix (computed)ComputedcomputedRSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
60Section 09b board cost (computed)ComputedcomputedCash 526,500 + equity 1,125,000 + all other 0 = 1,651,500, summed across the director compensation table rows.machine: formula: Σ = 1,651,500
61Day One Biopharmaceuticals, Section 10b CEO totalDEF 14A2025-04-110001140361-25-013462CEO total compensation as printed in Day One Biopharmaceuticals's own proxy. As printed: 6,560,577. Filing ↗machine: r2 · c21 · span 526324–526333
62Replimune Group, Section 10b CEO totalDEF 14A2026-07-290001104659-26-087650CEO total compensation as printed in Replimune Group's own proxy. As printed: 5,845,982. Filing ↗machine: r1 · c41 · span 430765–430774
63Precigen (subject), Section 10b CEO totalDEF 14A2026-04-300001140361-26-018214CEO total compensation as printed in Precigen's own proxy. As printed: 5,354,329. Filing ↗machine: r2 · c24 · span 721439–721448
64Aura Bioscience, Section 10b CEO totalDEF 14A2026-04-200001193125-26-163933CEO total compensation as printed in Aura Bioscience's own proxy. As printed: 3,956,167. Filing ↗machine: t10 · r2 · c29 · span 480151–480160
65Rocket Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-060001140361-26-013335CEO total compensation as printed in Rocket Pharmaceuticals's own proxy. As printed: 3,510,241. Filing ↗machine: r2 · c24 · span 348766–348775